Anthrax PA Antibody Blocking Peptide

• Reactivity: V
• Applications: AC
• Concentration: 1 mg/ml

Anthrax PA Antibody Blocking Peptide Summary

• Specificity: This peptide is specific for NB100-55743 only.
• Protein/Peptide Type: Antibody Blocking Peptide

Applications/Dilutions

• Dilutions:
  • Antibody Competition
• Application Notes: This peptide is useful as a blocking peptide for NB100-55743. For further blocking peptide related protocol, click here.

Packaging, Storage & Formulations

• Storage: Store at -80C. Avoid freeze-thaw cycles.
• Buffer: Peptide dissolved in dH20. Contains no BSA.
• Preservative: No Preservative
• Concentration: 1 mg/ml

Alternate Names for Anthrax PA Antibody Blocking Peptide

• anthrax PA
• Anthrax toxins translocating protein
• Bacillus anthracis protective antigen
• PA 83
• PA
• PA83
• PAG
• Paga
• Protective antigen

Background

Anthrax PA (Protective Antigen) and Anthrax LF (Lethal Factor), along with Anthrax EF (Edema Factor), are toxins produced by Bacillus anthracis. All three of the proteins must be present for toxic entry into cells. PA is secreted from Bacillus anthracis as an 83 kDa (PA83) protein which is cleaved by furin protease, releasing a 20 kDa fragment. The 63 kDa portion (PA63) of the cleavage product forms a heptamer, which binds the toxins LF and EF. This complex enters via receptor-mediated endocytosis where LF and EF exert their toxic effects.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Peptides and proteins are guaranteed for 3 months from date of receipt.